Dermata Therapeutics has secured a significant patent grant from the Australian Patent Office for its innovative DMT410 program, marking a key milestone in the development of needle-free botulinum toxin delivery for hyperhidrosis treatment. The patent, titled "Compositions for the treatment of skin conditions" (Australian Patent No. 2109284621), represents the company's second granted patent for this groundbreaking technology.
Novel Delivery System Shows Clinical Promise
DMT410 represents a paradigm shift in botulinum toxin administration, utilizing Dermata's proprietary XYNGARI™ product candidate to enable topical delivery rather than traditional needle injections. The treatment protocol involves an initial topical application of XYNGARI™, where microscopic spicules penetrate the stratum corneum to create microchannels into the dermis, allowing subsequent topical application and penetration of botulinum toxin.
"We are thrilled to be granted this Australian patent, a testament to our team's relentless innovation and dedication to providing patients with unique and novel treatment options," said Gerry Proehl, Dermata's Chairman, President, and CEO. "We believe this patent reinforces our commitment to pushing boundaries for standard of care for hyperhidrosis patients and delivering groundbreaking solutions that we believe can transform the lives of patients."
Clinical Development Progress
The company has successfully completed proof-of-concept Phase 1 clinical trials using DMT410 in combination with BOTOX® for primary axillary hyperhidrosis treatment and multiple aesthetic skin conditions. Both studies demonstrated promising efficacy results and appeared to be safe and well tolerated by patients.
Building on these positive results, Dermata is planning to initiate a Phase 2a study of DMT410 combining XYNGARI™ with DAXXIFY® for axillary hyperhidrosis treatment. The company has also recently entered into a Clinical Trial Collaboration Agreement with Revance to further study DMT410 for axillary hyperhidrosis treatment.
Addressing Unmet Medical Needs
The technology's potential extends beyond axillary hyperhidrosis to address significant unmet medical needs in palmer and plantar hyperhidrosis treatment. "We are excited about the opportunities the DMT410 program can bring to patients, not only for the treatment of axillary hyperhidrosis, as we have seen in our proof-of-concept study, but potentially for palmer and plantar hyperhidrosis, which remain high unmet needs for patients," Proehl added.
Spongilla Technology Platform
DMT410 leverages Dermata's broader Spongilla technology platform, which is based on naturally sourced freshwater sponge materials. The company's lead product candidate, XYNGARI™ (formerly DMT310), is a once-weekly topical treatment derived from this platform that recently achieved positive data in a Phase 3 STAR-1 study for moderate-to-severe acne treatment.
The Spongilla technology platform has demonstrated versatility across multiple dermatological conditions, with XYNGARI™ having been studied for acne, psoriasis, and rosacea treatment, while DMT410 expands its application to botulinum toxin delivery for both aesthetic and medical skin conditions.
Intellectual Property Strategy
This Australian patent grant continues to strengthen Dermata's global intellectual property portfolio for DMT410 hyperhidrosis treatment. The patent protection supports the company's position in developing needle-free alternatives to traditional botulinum toxin injection therapies, potentially offering improved patient compliance and treatment accessibility.
